


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claim 1. (Original): A compound which is an agonist of the S1P4 receptor, wherein said compound possesses a selectivity for the S1P4 receptor over one or more of the S1P1, S1P2, S1P3 or S1P5 receptors of at least 10 fold, as measured by the ratio of the EC<sub>50</sub> of the compound for the S1P4 receptor to the EC<sub>50</sub> of the compound for the S1P1, S1P2, S1P3 or S1P5 receptor, in free form or in a pharmaceutically acceptable salt form.

Claim 2. (Original): A compound of formula I



wherein

R<sub>1</sub> is phenyl or naphthyl, wherein phenyl is substituted by one or two of halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy or phenylC<sub>1-6</sub>alkyl; and

R<sub>2</sub> is hydrogen or C<sub>1-6</sub>alkyl;

in free, hydrate or salt form.

Claim 3. (Currently amended): A compound according to claim 1 ~~or claim 2~~ which is selected from 3-(4-(2-Ethylphenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-benzyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(naphthalen-2-yl)-2-carboxamido-indole)-alanine, 3-(4-(naphthalen-1-yl)-2-carboxamido-indole)-alanine, 3-(4-(2-butoxy-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-propyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-isopropyl-phenyl)-2-carboxamido-indole)-alanine, and 3-(4-(2,4-dichloro-phenyl)-2-carboxamido-indole)-alanine, or a pharmaceutically acceptable salt therefor.

Claim 4. (Original): A compound according to claim 3 which is 3-(4-(2-Ethylphenyl)-2-carboxamido-indole)-D-alanine, in free form or in a pharmaceutically acceptable salt form.


Claim 5. (Currently amended): A compound according to ~~any one of claim 1 to 4~~ 1-4, in free form or in a pharmaceutically acceptable salt form, for use as a pharmaceutical.

Claim 6. (Currently amended): A pharmaceutical composition comprising a compound as defined in ~~any one of claim 1 to 4~~, in free form or in a pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.

Claim 7. (Canceled)

Claim 8. (Currently amended): A pharmaceutical combination comprising a compound according to ~~any one of claim 1 to 4~~ in free form or in a pharmaceutically acceptable salt form and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory and chemotherapeutic drug agents.

Claim 9. (Original): A process for the production of the compound according to claim 2, which process comprises deprotecting a compound of formula II



wherein R1 and R2 are as defined in claim 2,

R6 is C1-6alkyl or benzyl,

R7 is an amino protecting group,

and optionally converting the compound of formula I obtained in free form to a salt form or vice versa.

Claim 10. (Currently amended): A method for treating or preventing disorders or diseases mediated by lymphocytes, acute or chronic transplant rejection, T-cell mediated inflammatory or autoimmune diseases, diabetes, allergic diseases, myocarditis, hepatitis, ischemia/reperfusion injury, renal failure, hemorrhage shock, traumatic shock, cancer or infectious diseases, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to ~~any one of claim 1 to 4~~, or a pharmaceutically acceptable salt thereof.